Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Goldman Sachs And Hedge Funds See Big Things For These Small-caps

4. Pacira Pharmaceuticals Inc (NASDAQ:PCRX)

 – Investors with Long Positions (as of June 30): 25

 – Aggregate Value of Investors’ Holdings (as of June 30): $367.67 Million

– Goldman Sachs Rating and Price Target: ‘Buy’ $90 (131% upside to the current trading level)

While the total number of hedge funds with investments in the specialty pharmaceutical company reduced by two since the end of March, the total value of hedge funds’ holdings, among those that we track, increased by about $113.38 million despite a drop in Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s stock price of about 18% during this period. The concentration of these holdings at June end stood at  14.30% in terms of the company’s market cap. Hoplite Capital Management, which is led by John Lykouretzos initiated a stake of 1.26 million shares in Pacira during the second quarter.

Follow Itron Inc. (NASDAQ:ITRI)
Trade (NASDAQ:ITRI) Now!

Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s star drug, the post surgical pain medicine Exparel, accounts for 99% of the company’s revenues and in the second quarter posted a 27% increase in sales on a year-over-year basis. Analysts estimate that the drug could boost the company’s EPS from $0.02 in 2015 to $5.84 in 2019. However, there are a number of companies that have similar drugs under development that could shrink Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s future revenues, but until then the company enjoys an almost monopoly in the market.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.